How is MCAS Diagnosed?

While MCAS is a real medical condition, diagnosing it is not straightforward. In this post, we’ll cover why a diagnosis matters, current diagnostic criteria, tests that may be ordered to support diagnosis, and challenges in diagnosis.

Disclaimer: I am not a medical professional. This post is for educational and exploratory purposes only and should not be taken as medical advice.

Motivation for Diagnosis

Getting a formal MCAS diagnosis can be a long and frustrating process, but it often makes a real difference. A diagnosis provides validation that what you’re experiencing is real and gives you shared language to use with doctors and insurers.

In practice, having a diagnosis usually means a doctor has entered an ICD code for MCAS (for example, D89.40) into your medical record. That code follows you across your chart, insurance claims, and referrals.

Practically, that can lead to:

• Insurance support for prescription medications: Coverage is not automatic since most MCAS treatments are off-label, but a diagnosis can strengthen prior authorizations for prescription drugs like cromolyn sodium or montelukast (read more about MCAS medications here).
• Stronger traction with specialist referrals: Having a diagnosis can make it easier to justify referrals to allergy, immunology, GI, or other specialists. Access still varies a lot by provider and region, but the diagnosis gives doctors a clearer reason to send you on (here is a patient-driven list of MCAS doctors by specialty and region).
• More credibility when advocating for accommodations: Whether with doctors, workplaces, or schools, a recognized diagnosis adds weight when you need ADA accommodations.

Which doctor assigns your diagnostic code matters as insurers tend to give more weight when the code comes from an allergy or immunology specialist rather than just a primary care provider.

That said, having a diagnosis won’t solve everything on its own. Most day-to-day recovery comes from managing symptoms, finding safe routines, and gradually building back stability.

Diagnostic Criteria

The most widely cited criteria for MCAS come from international consensus groups of allergy and immunology specialists. These were first outlined by Dr. Peter Valent and colleagues in 2012 and later refined in 2022 with contributions from European Competence Network on Mastocytosis (ECNM) and American Academy of Allergy, Asthma & Immunology (AAAAI) experts. Their goal was to create consistency in a field where diagnoses varied widely.

Their guidelines describe three main pillars:

1. Symptoms in two or more organ systems: For example, flushing with GI upset, or dizziness with abdominal pain, or combinations of cardiovascular, respiratory, and neurological symptoms.
2. Objective lab evidence of mast cell activity: Most often elevated tryptase, prostaglandin, histamine, or leukotrienes.
3. Response to treatment: If symptoms improve with antihistamines, leukotriene inhibitors, or mast cell stabilizers, that supports the diagnosis.

The pillars were meant to standardize both research and clinical care, but they’re applied most strictly in research, which is why they can feel misaligned with day-to-day experience. As a result, not all doctors use these criteria the same way. Some (like Valent) emphasize strict lab evidence and narrow criteria, while others (like Afrin) argue for a more inclusive clinical approach, noting that many patients can’t capture a flare on lab testing. Whether you fit the criteria can depend on which doctor is applying them.

In practice, that means:

• The consensus criteria shape how allergists and immunologists are trained to recognize MCAS.
• Insurance companies and academic centers tend to reference the stricter versions.
• In clinical care, many doctors still rely on pattern recognition by ruling out other conditions, observing symptoms across multiple organ systems, and seeing whether mast-cell–directed medications help.

Diagnostic Tests

No single “MCAS test” exists. Instead, doctors may order a variety of tests to detect the presence of mast cell mediators in the body, including:

• Serum tryptase: A blood test measured both at baseline and again during or shortly after a flare. Baseline tryptase reflects the number of mast cells in the body, which is why it is usually elevated in systemic mastocytosis but often normal in MCAS. In MCAS, mast cells are hyper-reactive rather than increased in number. A transient rise during a flare can support diagnosis, but it is easy to miss unless blood is drawn within about 1–4 hours. Genetic factors like hereditary alpha-tryptasemia can also affect baseline levels.
• 24-hour urine collection: A urine test collected over a full day, ideally during a period when symptoms are active. Labs measure mediators such as N-methylhistamine, prostaglandin D2 (or its metabolite 11-β-PGF2α), and leukotriene E4. These markers can provide supportive evidence but are unstable and may degrade if samples are not handled properly. Histamine itself can also increase urine production, which may dilute the sample, and not all labs adjust for total volume or creatinine when reporting results.
• Chromogranin A: A blood test that measures a protein found in many neuroendocrine cells, including small amounts in mast cells. Sometimes elevated in mast cell activation, but not specific as levels can also rise with certain medications (such as proton pump inhibitors) or other health conditions.
• Tissue biopsy: Taken during procedures such as endoscopy or colonoscopy. Samples are examined for abnormal mast cell numbers, clustering, or activation markers. More often used to rule out systemic mastocytosis, but sometimes provides supporting evidence for MCAS.

These tests are not straightforward. Mast cell mediators break down quickly, so timing (ideally during or just after a flare) and proper sample handling are critical. Even when done correctly, false negatives are common, meaning that normal test results do not rule out MCAS. Because of this, lab tests are best viewed as supporting evidence rather than a definitive answer.

Challenges & Future

Getting an MCAS diagnosis is rarely straightforward.

• Symptom overlap: Signs of mast cell activation (flushing, abdominal pain, diarrhea, dizziness, brain fog, rashes ) overlap with many other conditions, including allergies, IBS, POTS, EDS, and autoimmune disorders. This makes it hard to know when mast cells are the driver versus part of a bigger picture.
• Inconsistent criteria: Different specialists use different definitions. Some require strict lab evidence, while others are more comfortable making a clinical diagnosis based on symptoms and treatment response.
• Limited awareness: Many doctors are still unfamiliar with MCAS. This often leads to delays, misdiagnosis, or symptoms being dismissed as anxiety, stress, or just “weird.”

Despite these challenges, there are reasons to be hopeful. Research interest in MCAS is growing, and diagnostic standards are slowly evolving. International working groups continue to refine criteria, and new studies are looking for more reliable biomarkers, including:

• Refining tryptase interpretation: The “20% + 2 ng/mL” formula is being validated as a more reliable way to confirm mast cell activation across different baseline levels, reducing the risk of missed events. Springer — Advances in MCAS Diagnosis
• Biomarkers in blood: Research is looking at markers beyond tryptase, including carboxypeptidase A3 and heparin, which may better reflect mast cell activity in some patients. PubMed — Biomarkers in the diagnosis of mast cell activation PubMed — Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
• Flow cytometry and surface markers: Identifying activation markers on mast cell surfaces could provide real-time evidence of degranulation. JACI In Practice — Flow Cytometry in MCAS
• Genetic contributions: Hereditary alpha-tryptasemia is being studied not only as a baseline tryptase modifier but also as a genetic risk factor for mast cell–related symptoms. PubMed — Hereditary alpha-tryptasemia and monoclonal mast cell disorders

The more the condition is recognized, the more likely it is that patients will gain access to clearer testing, better insurance support, and more consistent care.